GLP-1 Drugs Improve Liver Health Even Without Weight Loss
News Context
At a glance
- New research confirms that semaglutide, the active ingredient in GLP-1 medications such as Wegovy and Ozempic, improves liver health independently of weight loss, offering therapeutic benefits even for...
- The findings, led by researchers at Toronto's Sinai Health, show that semaglutide acts directly on a subset of liver cells to reduce inflammation, scarring and elevated enzyme levels...
- “We’ve seen in clinical trials that patients who lose very little weight see the same reductions in liver inflammation, scarring and enzyme levels as those who lose a...
New research confirms that semaglutide, the active ingredient in GLP-1 medications such as Wegovy and Ozempic, improves liver health independently of weight loss, offering therapeutic benefits even for patients who do not experience significant weight reduction.
The findings, led by researchers at Toronto’s Sinai Health, show that semaglutide acts directly on a subset of liver cells to reduce inflammation, scarring and elevated enzyme levels associated with metabolic dysfunction-associated steatohepatitis (MASH), a serious liver condition projected to affect nearly 2 billion people worldwide by 2050.